Previous 10 | Next 10 |
Turnkey research facility expands network in San Diego, San Francisco, Thousand Oaks and Seattle Charles River Laboratories International, Inc. (NYSE: CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in Califor...
Charles River Laboratories ( NYSE: CRL ) on Tuesday said it had got a good manufacturing practice certification from Europe's drug regulator to commercially produce and distribute allogeneic cell therapy drug products. CRL said the approval came after an inspection of ...
Company awarded commercial GMP license following successful EMA inspection of Memphis CDMO facility Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to co...
Charles River Laboratories International, Inc. (CRL) Q2 2022 Earnings Conference Call August 3, 2022 9:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executive Officer Flavia...
Charles River Laboratories ( NYSE: CRL ) stock fell ~9% on Aug. 3 after the company reduced its FY22 outlook citing headwinds associated with CDMO business, foreign exchange, and interest expense due to the rising interest rate environment. Q2 non-GAAP EPS rose ...
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Charles River Laboratories International, Inc. 2022 Q2 - Results - Earnings Call Presentation
Charles River Laboratories press release ( NYSE: CRL ): Q2 Non-GAAP EPS of $2.77 beats by $0.03 . Revenue of $973.1M (+6.4% Y/Y) misses by $22.02M . The company’s updated guidance for revenue growth, earnings per share, and cash flow is as follows :&...
– Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance – Charles River Laboratories International, Inc. (NYSE:...
Charles River Laboratories ( NYSE: CRL ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $2.74 (+5.0% Y/Y) and the consensus Revenue Estimate is $995.12M (+8.8% Y/Y). Over the last 2 years, CRL ...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...